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 Unacceptable levels of Mycobacterium tuberculosis transmission are noted in high burden settings and a renewed focus on reducing person-to-person transmission in these communities is needed. We review recent developments in the understanding of airborne transmission. We outline approaches to measure transmission in populations and trials and describe the Wells–Riley equation, which is used to estimate transmission risk in indoor spaces. Present research priorities include the identiﬁcation of eﬀective strategies for tuberculosis infection control, improved understanding of where transmission occurs and the transmissibility of drug-resistant strains, and estimates of the eﬀect of HIV and antiretroviral therapy on transmission dynamics. When research is planned and interventions are designed to interrupt transmission, resource constraints that are common in high burden settings—including shortages of health-care workers—must be considered.  
Introduction Sustained reductions in disease incidence of up to 20% per year are required to meet the targets set out in the WHO End TB Strategy.1,2 However, incidence is currently only estimated to be reducing at 1·5% per annum.3 This trend is consistent with model predictions with respect to the probable eﬀect of present control strategies,4 which focus on case detection and treatment completion.5 Even in areas with good rates of case ﬁnding and treatment completion, evidence suggests that transmission is an issue. Although quality data for active tuberculosis in children younger than 5 years are scarce, the incidence of paediatric cases indicate continuing high levels of transmission.3,6,7 Tuberculin surveys in high prevalence countries estimate annual risks of Mycobacterium tuberculosis infection of 0·3–2·2%,8–12 but exceeding 5% in some parts of southern Africa.13,14 Test reversions (negative tests in people who previously had a positive test) mean such cross-sectional surveys might underestimate transmission.15 Data for M tuberculosis transmission derived from molecular typing methods from high burden areas are limited to a small number of research active settings. Nevertheless, these data suggest more disease results from recent transmission than from reactivation of latent tuberculosis,16,17 particularly in people living with HIV.18 The rapid rebound in tuberculosis incidence after the discontinuation of isoniazid preventive treatment (IPT) in southern African studies suggest continuing transmission is important in high burden settings,19,20 although models predict a contribution from reactivation disease implying IPT might not sterilise.21,22 To achieve the goals of the End TB Strategy,2 an increased  emphasis  on  reducing   person-to-person   M tuberculosis transmission in high burden settings is needed.   This   Review   summarises    research    into  M tuberculosis transmission in these settings. We focus on the biology of airborne M tuberculosis transmission, measuring transmission in populations, and modelling transmission with the Wells–Riley approach. We  conclude by identifying research priorities. We do not discuss transmission-blocking vaccines or mixed infections, each the subject of a recent review article.23,24 Of note, no international consensus exists for tuberculosis incidence or prevalence thresholds that deﬁne high burden, although a tuberculosis incidence of  100  cases  per  100 000 people per year has been used by WHO.25 Most of the studies we review were implemented in communities with a tuberculosis incidence of 100 cases or more per 100 000 people per year.  
Airborne M tuberculosis transmission Although M tuberculosis complex organisms can be spread through unpasteurised milk, direct inoculation, and other means, we focus on the predominant route, airborne transmission. The fundamentals of  airborne M tuberculosis transmission were  described  by William Frith Wells, Richard Riley, Robert  Loudon,  Rena Roberts, and others, more than 60 years ago.26 Recent progress in basic and clinical sciences has improved our understanding of M tuberculosis transmission, which had remained largely unchanged for more than 50 years. However, much remains unknown. Interruption of any process in the natural history of M tuberculosis will reduce rates of transmission at a population level (ﬁgure).  Individuals  with  pulmonary  tuberculosis  aerosolise  M tuberculosis, placing their contacts at risk of infection (ﬁgure). This aerosolisation occurs at a faster rate during coughing.27 Some evidence suggests that speech and singing are eﬀective aerosol generating activities,28,29 although these studies focused only on droplets originating in the mouth. Although the largest respiratory droplets fall to the ground, rapid evaporation means many droplets attain a suﬃciently low mass before settling so that they remain suspended in air currents until either inhaled or ventilated out of the room.30 Important new insights into M tuberculosis transmission have come from cough box experiments.31 In these studies, tuberculosis patients were asked to cough as frequently as was comfortable for 5 min into a cough aerosol sampling system. Although this procedure might not represent real physiological processes, these experiments suggest that most M tuberculosis that is aerosolised during coughing is in droplets small enough, even without evaporation, to remain suspended in the air.31 These cough box experiments,31,32 consistent with studies from guineapig facilities33,34 and molecular epidemiological observations,35–37 suggest that some people with tuberculosis might be much more infectious than others. Early animal experiments showed that M tuberculosis in smaller droplets more readily produced tubercles in  the  lung  than  did  M tuberculosis in larger droplets, presumably because these small droplets escape ﬁltration in the upper 
 airways.38,39 The use of surgical masks by patients with tuberculosis has been shown to reduce transmission to guineapigs by 56%, suggesting they partly block aerosolisation of the relevant respiratory droplets.40  The quantity and characteristics of the inhaled droplet can predict clinical outcomes, with early experiments showing that the infectious dose predicts the risk of infection and progression to disease.41 In the cough box experiments, the quantity of aerosolised M tuberculosis produced by individuals predicted infection in household contacts better than the smear grade or time to culture positivity.32 Larger droplets, settling in the upper airway, might result in immune memory and a positive test for infection but little risk of progression to disease.41 The fact that some highly exposed individuals do not develop positive tuberculin skin tests (TSTs) or interferon-gamma release assays (IGRAs) and the discovery of genetic loci that predict TST positivity suggest that the body can clear M tuberculosis infection without development of an adaptive immune response—so-called early clearance.42 This process is probably important epidemiologically but, because no evidence of the early clearance is left, is diﬃcult to study. Informed by animal studies and advanced imaging techniques, appreciation is growing for the opinion that a binary classiﬁcation of tuberculosis into latent infection and active disease might be too simplistic.43,44 Some individuals with positive tests for infection might have cleared the mycobacteria and periods of active replication in latent tuberculosis have been reported.43,44 Pulmonary M tuberculosis infection towards the more active end of the infection-to-disease range is probably necessary for infectiousness.  A widely-held view is that the infectiousness of patients diminishes suﬃciently after 2 weeks of antituberculous treatment such that transmission to contacts is unlikely.45 Many guidelines rely on proxy measures of infectiousness—eg, smear status or culture conversion. Of note, median time to culture conversion in patients treated with daily direct observation for drug-susceptible tuberculosis in Peru was much longer than 2 weeks    at 37 days.46 However, in patients on treatment, the association between sputum smear or culture status and infectiousness is not straightforward,47–51 and is likely to be  inﬂuenced  not  only  by  mycobacteria  viability     in respiratory secretions but also by the capacity to generate aerosolised M tuberculosis through coughing.27 Because cough frequency diminishes with treatment,52 assumptions about infectiousness on the basis of culture conversion times might overestimate risk. Furthermore, organisms that propagate in culture might not thrive when exposed to a hostile immune system in the alveoli. Infectiousness can be studied in guineapig facilities in which the number of animals infected after exposure to air exhausted from isolation rooms containing patients with tuberculosis is measured. Such experiments show that eﬀective treatment is associated with decidedly fewer M tuberculosis infections than are reported before treatment is initiated or when isolates are not fully susceptible to the treatment regimen.34,51 However, the guineapigs in these experiments were exposed to the patients for many weeks. Thus, these experiments have not yet reliably established a time window after which a patient can be deemed to be no longer infectious. Most, if not all, household contacts are more likely to be infected by an index patient in the pretreatment period than once treatment is initiated due to both the likely longer duration of exposure and the greater infectiousness pretreatment.53 This situation might also be true for patients with drug-resistant tuberculosis, in whom culture conversion times will typically be longer than those with drug-susceptible tuberculosis, particularly if initiation of eﬀective treatment is delayed.  
Measuring transmission in populations Even in the highest burden communities, the prevalence and annual incidence of active tuberculosis disease rarely exceed 2%. Infrequent outcomes, in combination with incomplete surveillance data and poor tests for infection, make the measurement of 
M tuberculosis transmission in populations a challenge.54 Inference about transmission therefore relies on proxy measures, assumptions, and combination approaches. The best approach to measure M tuberculosis transmission in trials of control interventions is controversial.55–57 Short-term reductions in disease prevalence, for example, are diﬃcult to interpret as prevalence is aﬀected not only by transmission but also by progression from infection to disease and disease duration.55 We have summarised frequently used tests for M tuberculosis infection (panel) andapproachestomeasurethe Mtuberculosis transmission in populations (table). Traditional approaches to measure transmission include tuberculin surveys in schoolchildren. Such surveys are a typical means of estimating M tuberculosis transmission at a population level. Although age assortative mixing might mean   paediatric   infections   do    not    fully    reﬂect  M tuberculosis transmission between adults,55,58,67 repeated TST surveys might still allow estimates of the trend in force of infection over time to be attained. Trend estimates based on tuberculin surveys are fairly robust and not greatly inﬂuenced by the proportion of children with BCG vaccine scars or the cut point used to deﬁne a positive test for infection.67,69 Molecular approaches include methods for strain typing M tuberculosis such as spoligotyping, which has low resolution; restriction fragment length polymorphism and mycobacterial interspersed repetitive units-variable number of tandem repeats,70–72 both of which have been widely used; and whole genome sequencing (WGS). These molecular epidemiological techniques provide evidence for or against potential linkages between two or more cases of active tuberculosis and have led to several crucial insights into M  tuberculosis  transmission.73 Since these techniques need a bacterial isolate, molecular epidemiology, with rare exceptions,74 captures only infections that have progressed to active tuberculosis disease.75 Molecular epidemiology cannot distinguish changes in transmission intensity from changes in the rate of progression to active tuberculosis shortly after infection resulting, for example, from varying levels of immunosuppression. The high resolution of 
 WGS and steep reductions in cost mean this technique is likely to eventually replace existing strain typing techniques. However, molecular epidemiology with WGS will need an understanding of the rate at which mutations occur. Recent studies37,76–78 suggest that, in active disease, single nucleotide polymorphisms (SNPs) emerge, on average, at half an SNP per M 
tuberculosis genome per year or slower. Most of the patients in these studies were on tuberculosis treatment and substantial variation was reported in the rate at which mutations occurred. A primate study suggests a similar mutation rate and that the mutation rate might not diﬀer substantially between active and latent infection.79 However, scarce data suggest that, in man, mutations accumulate more slowly during latent infection than in active infection.80 Occasional accelerated intrapatient microevolution events81 and the slow rate at which SNPs accumulate might make inference of chains of transmission from M 
tuberculosis genotypes alone challenging. Probabilistic models that also incorporate epidemiological and clinical data might be needed.82 With molecular epidemiology by WGS, as with older strain typing techniques, adequate study duration, a high sampling fraction, and careful documentation, follow-up, and reporting are important.16,83–85 However, novel approaches to the analysis of sequence data might allow population level inferences to be made from a smaller number of people than the older genotyping techniques.  Direct detection of aerosolised M tuberculosis in samples of room air is of great interest. This ability might allow quantiﬁcation of 
M tuberculosis exposure in putative sites of transmission. A few demonstration studies86–88 of PCR with room air ﬁltrate suggest that this detection might be feasible. Although PCR detection of M tuberculosis DNA does not necessarily mean organisms are viable, it would suggest that individuals with pulmonary tuberculosis have produced bioaerosols in the space. This ﬁnding should be, at least in theory, a reasonable proxy for transmission risk.  
Panel: Diagnostic tests of Mycobacterium tuberculosis infection 
• No gold standard diagnostic test exists for Mycobacterium tuberculosis infection. 
• The two widely used diagnostic tests are tuberculin skin tests (TSTs) and 
interferon-gamma release assays (IGRAs). Positive tests are interpreted as showing a previous adaptive immune response to mycobacterial infection. 
• Detection is not possible for infections cleared by the innate immune system before an adaptive response,42  nor is it possible to distinguish cleared infections that 
leave a lingering immunological footprint from persistent infection. 
• Neither test is able to distinguish between latent infection and disease. 
Tuberculin skin tests 
• TSTs use an intradermal injection of a standardised puriﬁed protein derivative then measurement of any induration after 48–96 h. 
• Sensitivity and speciﬁcity are dependent on the number of millimetres of induration chosen as the cut point and the prevalence of non-speciﬁc reactions 
resulting from exposure to environmental mycobacteria or previous BCG vaccination.58 The BCG eﬀect wanes in children vaccinated in infancy. 
• Low sensitivity can be seen with advanced age and with immunosuppression as a result of malnutrition or HIV. 
• New statistical techniques can suggest appropriate cut points for given distributions of reaction sizes.59 
• Test reversions do occur and are more common in young individuals, probably reﬂecting an initial false positive test.60 
Interferon-gamma release assay 
• IGRAs require a blood sample to be taken from patients. T cells are then exposed to antigens that are found in M tuberculosis but not in BCG or in most 
environmental mycobacteria. 
• Interferon-gamma released by cells that recognise these antigens is then assayed in the supernatant after incubation or by counting the number of 
interferon-gamma producing cells in an enzyme-linked immunospot assay. 
• IGRAs are a more speciﬁc test for M tuberculosis infection but less precedent exists for their use in transmission studies. The need for phlebotomy and the high 
cost of the test are also disadvantages. 
• Test reversions are common and the clustering of results around the threshold for positivity means the choice of cut point can substantially aﬀect sensitivity, 
speciﬁcity, and prevalence estimates.15 
New methods 
• A new and, hopefully, more speciﬁc skin test based on similar antigens to those used in IGRAs is now being tested in phase 3 trials.61 
• RNA expression signatures have been developed that might distinguish disease from latent infection, tuberculosis from other diseases, and that might revert 
after successful treatment of active tuberculosis.62–65 These signatures need further validation.   
The Wells–Riley equation Room ventilation and social contact patterns predict whether other individuals are exposed to M tuberculosis that has been aerosolised. The Wells–Riley equation is used to model the transmission of respiratory pathogens,89 such as M tuberculosis, that are spread by crowd rather than close contact. Transmission risk in a deﬁned space over time t is modelled as a Poisson process:  Probability of transmission = 1 – e –Iqpt/Q  where I is the number of infectious individuals present, q is the rate at which infectious individuals produce quanta, p is the 
 rate at which susceptible individuals breathe, and Q is the rate at which air from the space is exchanged with uncontaminated air (ventilation).  Riley and colleagues deﬁned quanta as “the number of infectious airborne particles required to infect which may be one or more airborne particles”.89 The  parameter q is often assumed or ﬁtted to data. Various attempts have been made to empirically estimate q for tuberculosis by venting air exhaled by patients with tuberculosis over experimental animals. Two sets of experiments in the pre-HIV era estimated quanta production at 0·62–0·82 and 1·25 per h with a heterogeneous group of tuberculosis patients.40,90–92 More recently, Escombe and colleagues34 obtained an estimate of 8·2 quanta per h in a group of patients living with HIV in Lima, Peru. These averages disguise huge heterogeneity in infectiousness with the most infectious patients in each study producing 60 and 226 infectious quanta per h.34,91,93 High rates of quanta production have been measured in patients with advanced multidrug- resistant tuberculosis,40 and very high rates estimated in outbreaks related to aerosol generating procedures.94 Interestingly, estimates of q obtained by ﬁtting to data from high burden communities are lower than those obtained empirically.95 This ﬁnding might be because untreated patients in the community are at an earlier stage in their illness and hence less infectious than the diagnosed patients used in the animal studies. The Wells–Riley equation has several important limitations. The equation assumes that air in the space is fully mixed and does not account for heterogeneity in infectiousness or susceptibility to infection. Adaptations to the equation have been published. One widely used variant uses a rebreathed fraction, the fraction of inhaled air that has been exhaled previously by someone in the building.96 This rebreathed fraction can be obtained from paired indoor and outdoor carbon dioxide (CO2) measurements. This process avoids the need to measure Q, which can be technically challenging. In many settings, spatial and temporal variations in CO2 concentrations are substantial. Not obtaining con- temporaneous CO2 measurements from directly outside the buildings studied might be reasonable in the absence of alternative CO2 sources and where wind speeds restrict local spatial and temporal variations in CO2. The absence of such contemporaneous measurements would not be reasonable in other circumstances. Several important insights have been derived from the Wells–Riley approach. For example, one study98 suggested that active case ﬁnding could not control high levels of M tuberculosis transmission in a South African prison if levels of overcrowding and poor ventilation were not also addressed. Another South African study,95 which used the equation to predict settings in which M tuberculosis transmission might occur, is described later in this Review.  
Research priorities Much    is   still   to   be   learned   about   M   tuberculosis transmission. Approaches to interrupting M tuberculosis transmission include active case ﬁnding, the provision of IPT, and tuberculosis infection control. Large trials have been completed into active case ﬁndings and mass IPT to interrupt M tuberculosis transmission. The ZAMSTAR56 result may be the ﬁrst empirical data suggesting that active  screening  for  tuberculosis   disease   reduces   M tuberculosis transmission at a population level.99 The Thibela tuberculosis trial,20 implemented in a setting with a very high incidence of infection, reported mass administration of IPT protected individuals whilst on treatment but had no eﬀect on tuberculosis incidence in the wider community.22  
Infection control Little research into tuberculosis infection control has been undertaken. Tuberculosis infection control is con- ventionally described in three domains—administrative controls (which aim to minimise contamination of shared air by infectious subjects—eg, cough triage, early diagnosis, and treatment), environmental controls (which aim to minimise exposure to M 
tuberculosis through disinfection or removal of contaminated air), and personal protection measures (which aim to minimise inhalation of contaminated air—eg, N95 respirators).100 A review of observational and animal studies101 concluded that the evidence is strong in support of the role of ventilation as an environmental control in reducing the risk of airborne transmission of M tuberculosis. Of the many ways to increase ventilation, increased mechanical ventilation,102 natural ventilation through increased window opening,103 and wind-driven roof turbines have been considered speciﬁcally as means to reduce M 
tuberculosis infection risk.104 Natural ventilation has been recommended by WHO as an eﬀective way to reduce infection.100 Air disinfection methods, particularly upper room ultraviolet germicidal irradiation, have also been studied leading to steep reductions in M  tuberculosis  transmission from tuberculosis patients to experimental animals.105,106 Implementation of environmental controls is not always straightforward. An increase in indoor levels of outdoor pollution, security concerns, exposure to outdoor hazards such as disease vectors, a loss of thermal comfort, energy loss through the exﬁltration of conditioned (heated or cooled) indoor air, and high running and maintenance costs of mechanical systems, are side-eﬀects of increased ventilation107 and might make such measures unacceptable to occupants. Therefore, the ideal retroﬁt and design measures used in a building should account for occupant patterns, numbers, and preferences, the climate and surrounding environment, building geometry, and the materials and budget available. Building simulation instruments might be used to predict the optimum design or retroﬁt of buildings to maximise ventilation according to speciﬁed criteria.108,109 The FAST approach to tuberculosis infection control in congregate settings has been promoted and    advocates “Finding TB cases Actively, Separating safely, and Treating eﬀectively”.110 A trial of the FAST approach is about to commence in Peru (NCT 02355223) using TST negative to positive conversions in health-care workers as an endpoint. However, the absence of a comparator group might limit the strength of the conclusions that can be reached. Although an association between ventilation rate and tuberculosis transmission is clear, little empirical evidence exists for the eﬀectiveness of infection control interventions in reducing transmission, with most studies using animal surrogates or ventilation measurements as a proxy for 
 transmission risk. A notable exception was the Tuberculosis Ultraviolet Shelter Study,111 which showed that environmental modiﬁcations can be safely implemented at scale.111 Although too few TST conversions occurred in residents of the shelters to show an eﬀect on M tuberculosis transmission, similar studies in high burden settings would be valuable to quantify the eﬀect of tuberculosis infection control interventions on transmission to human occupants and, potentially, on transmission in the surrounding community.112 Whether household infection control implemented at diagnosis can mitigate against secondary infections in patients managed in the community is not known. To our knowledge, no trials of such interventions have been implemented. This question is important, perhaps in multidrug-resistant tuberculosis and certainly in extensively drug-resistant tuberculosis, in which chemotherapy might not promptly reduce infectiousness and where the consequences of transmission might be severe.  
Locating M tuberculosis transmission Historically, households have been deemed to be a major focus of M tuberculosis transmission. However, three molecular epidemiological studies17,113,114 from sub- Saharan Africa and one from rural Vietnam,115 all suggest that most transmission occurs between, rather than within, households. In these high burden settings, this ﬁnding probably reﬂects a high transmission risk outside the home rather than a reduction in the risk of transmission to household contacts. Other evidence also suggests that, overall, most transmissions occur outside the household,116,117 but studies suggest this result is age dependent with young children more likely to have been infected by a household member.118–120 Transmission in indoor congregate settings is probably important in high burden settings. For example, time working in public transport is strongly associated with TST positivity in Lima, Peru.121 Understanding which settings are important should be a research priority, because this knowledge would allow infection control and active case ﬁnding interventions to be better targeted.112 The Wells–Riley equation and its variants have been used to estimate M tuberculosis transmission risk by location. Studies adopting these approaches have estimated ventilation  or  likely  exposure  to  exhaled  bioaerosols based on CO2 levels. These methods have been applied to study transmission in a Cape Town, South Africa, township. Data were collected for CO2 concentrations in various settings visited by 63 adolescents. 93% of total exposure to rebreathed air was estimated to occur in a few locations: 
own home, visited homes, public transport, work, or school.97 The same research group used a modiﬁed Wells–Riley equation, CO2 measurements, and social contact pattern data to estimate the proportion of overall M tuberculosis transmission by location. The researchers reported that, in the same Cape Town township, 50% of incident infections in 15–19 year olds might take place in school, that workplaces are important places for adult transmission, and that household and public transport might be important sites of transmission between age groups.95 These inferences are potentially useful but the studies were small in terms of geographical extent and participant numbers. The conclusions might be context speciﬁc and assume tuberculosis disease prevalence is the same in each location within an age and sex group, which is probably not the case. Similar studies need to be undertaken on larger scales and in more settings, ideally combined with location speciﬁc estimates of tuberculosis prevalence. Health facilities, particularly in HIV endemic areas, are an important setting in which patients infectious with tuberculosis mix with susceptible people. People with infectious tuberculosis attend health-care facilities before diagnosis, when presenting with tuberculosis symptoms, and during the course of tuberculosis treatment. Delays in recognition, diagnosis, and isolation of infectious cases augment the risk of nosocomial transmission from unsuspected index cases. Overcrowded outpatient clinics and emergency departments congregate people at risk of progressing from infection to disease in settings where the likelihood of exposure to patients with infectious tuberculosis is relatively high. In a study122 based in an emergency department in Lima, Peru, IGRA conversion was reported in 30% of health-care workers during a   12 month period compared with 0% of hospital security and domestic personnel; remarkably a third of patients identiﬁed with tuberculosis in the study were attending the hospital for an apparently unrelated reason (trauma, pregnancy, etc) showing the importance of the unrecognised risk. Nosocomial transmission played an important part in the Tugela Ferry, South Africa, extensively drug-resistant tuberculosis outbreak.123 Future research should quantify the proportion of M tuberculosis transmission in high burden settings that occurs within health-care facilities and the eﬀect of programmatic infection control interventions on this proportion. Spatial heterogeneity in the incidence of tuberculosis and drug-resistant tuberculosis is evident in analyses of programmatically collected data and has been well documented in many studies,124–126 raising the possibility that targeted interventions might be eﬀective. At this time, however, the mechanisms driving such heterogeneity are not completely understood—eg, localised transmission and/or aggregation of individuals sharing risk factors for infection or progression might combine to generate such patterns of disease. An improved understanding of this spatial heterogeneity might usefully inform targeted tuberculosis control interventions. Improved data for the geographical extent of social contacts relevant for tuberculosis transmission would assist in the design of intervention studies. Research addressing this question would be valuable. 
Search strategy 
We searched all studies published before Oct 1, 2015, in 
PubMed. We sought articles published in English using the 
terms “tuberculosis”and “transmission”. We also included 
papers from the reference lists of these papers and all authors 
suggested papers for inclusion in the Review. 
  
Drug resistance and transmissibility Globally, an estimated 480 000 incident cases of multidrug-resistant tuberculosis occurred in 2013. The proportion of new cases that are infected with multidrug- resistant tuberculosis is about 3·5% and this percentage has not changed noticeably over the period of 2008 to 2013.3 Multidrug-resistant tuberculosis is dispro- portionately distributed, with the highest rates reported in central Asia and eastern Europe where, in several countries, a high proportion of multidrug-resistant tuberculosis cases have no previous history of tuberculosis treatment.3 This ﬁnding suggests high levels of multidrug-resistant tuberculosis transmission. Projections of the future burden of multidrug-resistant tuberculosis depend crucially on estimates of the reproductive potential of drug-resistant strains as compared     with     drug-sensitive     strains.127,128 This reproductive potential, which can be quantiﬁed as the expected number of secondary infectious cases attributable to a single infectious case, is the product of several factors: the duration of infectiousness, the rate at which respiratory exposures occur, the probability that exposure results in transmission, and the probability that infection progresses to infectious  active  disease.129  Drug resistance might aﬀect several of these factors. For example, the duration of infectiousness is often longer in individuals with multidrug-resistant tuberculosis because delays in the diagnosis of resistance can lead to delayed initiation of eﬀective treatment. However, the probability of exposure causing a secondary infectious case might be decreased if resistance-conferring mutations have a ﬁtness cost.130 In-vitro experiments (eg, competitive growth assays that measure biological ﬁtness) and observational studies (eg, contact tracing and molecular clustering studies, which measure eﬀects of biological ﬁtness and diﬀerences in duration of infectiousness) suggest a wide variation in the association between drug resistance and transmission.131 Further- more, even where clear biological costs are associated with resistance, these costs can be ameliorated by compensatory mutations.132,133 WGS analyses of clinical strains suggest successful transmission of multidrug- resistant strains in disparate settings, such as South Africa and Russia.134,135 However, a household contact study136 suggested     circulating     multidrug-resistant tuberculosis strains in Peru were less likely to result  in disease in household contacts than drug-sensitive strains. The data for transmission of extensively drug-resistant M tuberculosis, at least during the time of observation, are also mixed.134,137 Because the ﬁtness of drug resistant strains might increase over time (as a result of selection or through compensatory mutations), these mixed results might reﬂect diﬀerences in the maturity of drug- resistant tuberculosis epidemics.138 In view of the importance of reproductive potential to projections of the multidrug-resistant and extensively drug-resistant tuberculosis epidemics, this topic is still a research priority.  
HIV and M tuberculosis transmission Our understanding of the eﬀects of HIV on M tuberculosis transmission is scarce.75 Some data suggest that people living with HIV with tuberculosis disease make a small overall contribution to M tuberculosis transmission. The arrival of HIV in Tanzania was associated with an increase in tuberculosis incidence but a reduction in annual risk of tuberculosis infection measured in a series of tuberculin surveys.69 The arrival of HIV in South Africa was associated with an obvious increase in tuberculosis incidence in people living with HIV but not those who were HIV negative.139 This ﬁnding was replicated in a prospective cohort study140 in business employees in Harare. These studies were completed before antiretroviral therapy was widely available. A household contact study141 suggests that transmission to household contacts is less frequent when the index case has more advanced HIV-related immunosuppression. Molecular epidemiology suggests that, in a South African township, HIV-negative people are more likely to be the index cases in strain clusters than HIV-positive people.17,142 However, a study78 in Malawi with WGS reported no association between HIV status or receipt of antiretroviral therapy (ART) and the probability of being linked to secondary cases. Several potential explanations exist for these observations. People living with HIV are more likely to have smear-negative or extrapulmonary disease, which are less infectious. Short disease duration due to fast progression to death or treatment might limit the opportunity to transmit,143 as might the reduced social contact as a result of greater morbidity. However, although people in HIV care might have their tuberculosis diagnosed faster, health-care facilities might be important sites of transmission. After publication of the START144 and ANRS TEMPRANO145 trials, WHO guidelines have been updated.146 ART is now recommended to be provided to all people living with HIV irrespective of CD4 cell count. In response, national policies are likely to be updated to recommend an earlier initiation of ART than recommended at present. ART reduces tuberculosis disease incidence rates in HIV cohorts by about two- thirds.147–149 Short-term reductions in population level tuberculosis disease rates have also been reported in communities in South Africa and Malawi, where ART has been scaled up rapidly.150,151 This ﬁnding might be largely explained by reduced progression from infection to disease rather than by reductions in transmission. The long-term eﬀect of ART on tuberculosis disease burden  at  the  population   level   and   the   eﬀect   on M 
tuberculosis infection incidence are uncertain. ART certainly aﬀects longevity, levels of contact with health- care services, and susceptibility to tuberculosis disease. ART might also aﬀect tuberculosis disease duration and phenotype, including the presence of cavities, smear positivity,152,153 and the frequency of extrapulmonary disease, all of which might aﬀect infectiousness. Furthermore, reduced morbidity as a result of ART might result in increased levels of social contact. An inﬂuential modelling study154 estimating the eﬀect of the roll-out of annual HIV testing and immediate ART on tuberculosis disease incidence in nine African countries predicted a 21% (range 10–31%) reduction in the cumulative AIDS-related tuberculosis disease incidence over the ﬁrst 5 years, and a 48% (range 37–55%) reduction in the incidence of tuberculosis disease 
 at 5 years. A multimodel analysis155 for the time period 2014–33, estimated that increasing ART coverage to 80% of those with a CD4 count of 350 cells per μL or less could reduce tuberculosis incidence by 8–14%. Additionally, if ART were provided to all HIV infected individuals (at present levels of access), incidence could be reduced by 6–30%. However, a more recent modelling study156 suggested that the long- term eﬀect of expanded ART access was less certain than the earlier models suggested. Although tuberculosis incidence should initially reduce, the model predicted that, if good adherence and immunological responses to ART are not sustained and combined with eﬀective HIV preventive interventions, increases in tuberculosis disease incidence might occur despite high levels of ART coverage.156 After publication of the new WHO guidelines,146 more people will probably start treatment with ART at higher CD4 counts than previously. In view of the substantial eﬀect—either positive or negative—that this new practice might have on tuberculosis in HIV endemic settings, the eﬀect of HIV and ART on transmission dynamics should be a focus of research.  
Conclusions Addressing M tuberculosis transmission is crucial to achieve control of tuberculosis in high burden settings. Repeated  surveys  measuring  tuberculosis  infection in the same community, including young adults, oﬀer a feasible measure of tuberculosis transmission. This approach might be used in trials in high burden settings to enable the eﬀect of interventions on transmission to be disaggregated from their eﬀects on rates of progression to disease or disease duration. The coming years will see innovative and exciting research on M tuberculosis transmission in high burden settings. Priority should be given to the development and assessment of strategies for tuberculosis control that place minimal additional demands on poor patients and overstretched health-care systems,112 or that include elements of social protection or health system strengthening. 
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What is measured? Advantages Disadvantages 
Prevalence of 
tuberculosis infection 
 
 
 
 
 
 
 
Incidence of 
tuberculosis infection 
 
 
 
 
Tuberculosis 
notiﬁcations 
 
 
 
 
 
Prevalence of 
tuberculosis disease 
 
 
 
 
 
 
Incidence of 
tuberculosis disease 
 
 
 
 
 
Molecular 
epidemiology 
(proportion clustered) 
Typically measured with tuberculin skin 
tests in school-age children 
 
 
 
 
 
 
 
Testing cohorts for tuberculosis infection 
longitudinally 
 
 
 
 
Notiﬁcations of tuberculosis disease to 
the national treatment programme 
 
 
 
 
 
Typically measured in large surveys by 
sputum culture with or without 
prescreening for symptoms and/or with a 
chest radiograph 
 
 
 
 
Measured in established cohorts or by 
two prevalence surveys 
 
 
 
 
 
The proportion of isolates that have the 
same strain type usually with RFLP, 
MIRU-VNTR, or WGS* 
Cheap and well established; infections must have occurred 
within an individual’s lifetime, hence, in young children, 
this test is a measure of recent infection; prevalence can 
be converted into an annualised incidence (ie, ARTI);58 
repeated surveys or continuous measurement of infection 
prevalence in the same age group can quantify changes in 
Mycobacterium tuberculosis transmission over time 
 
 
Older children can be included and inferences still made 
about recent transmission; an incidence cohort including 
older children and adults provides a general insight into 
transmission in the community even if mixing patterns 
are strongly age assortative 
 
Data are routinely captured; enhancement of capacity to 
diagnose and notify cases of tuberculosis might be 
possible for the purposes of research, although substantial 
biases and quality problems inherent to routinely 
collected data are likely to persist 
 
 
Well established; undiagnosed individuals can be referred 
for treatment 
 
 
 
 
 
 
Allows changes in incidence to be disaggregated from 
changes in disease duration 
 
 
 
 
 
Allows inferences to be made about the proportion of 
tuberculosis resulting from reactivation versus recent 
infection; strain typing can disprove or provide evidence 
to support putative transmission events 
Does not capture early clearance; poor sensitivity and 
speciﬁcity, uncertainty with respect to cut points plus 
conversions and reversions of test positivity can aﬀect 
estimates in some populations; from a study at only one 
timepoint, age and cohort eﬀects cannot be separated; Styblo’s 
rule, which states that ARTI and the incidence of tuberculosis 
disease have a ﬁxed association, is no longer thought to be 
valid;66,67 WHO no longer recommends single tuberculin skin 
test surveys 
Does not capture early clearance; needs larger sample or longer 
duration of follow-up than measurements of infection 
prevalence; losses to follow-up might reduce power and bias 
estimates; exclusion of those who are positive at baseline 
might exclude those at highest risk—a particular issue in older 
individuals in high burden settings 
Serious problems with data quality in most high burden 
settings; captures only tuberculosis transmission that 
progresses to disease; captures only individuals who access a 
diagnosis and whose diagnosis is notiﬁed; might capture 
individuals who do not have tuberculosis—poor speciﬁcity is a 
particular issue where tuberculosis diagnosis is mainly on the 
basis of chest radiographs, such as in children 
Substantial and expensive undertaking; captures only 
tuberculosis transmission that progresses to (pulmonary) 
disease; whether changes in prevalence are a result of 
diﬀerences in transmission, in progression from infection to 
disease, or in disease duration, might not be clear; prevalence 
surveys are active case ﬁnding interventions and will 
transiently change local tuberculosis epidemiology; sputum 
culture has low sensitivity in children 
Except in established cohorts in high burden settings, the 
measurement of incidence needs more than one large 
prevalence survey, which is rarely feasible; captures only 
tuberculosis transmission that progresses to (pulmonary) 
disease; whether diﬀerences in prevalence are a result of 
variation in transmission or in progression from infection to 
disease is not clear 
Needs advanced laboratory capacity; captures only 
transmissions that progress to disease and isolates that are 
sampled; biased estimates can be obtained if the sampling 
fraction is low, if the study is not of suﬃcient duration, or if 
substantial in or out migration of participants takes place 
ARTI=annual risk of tuberculosis infection. RFLP=restriction fragment length polymorphism. MIRU-VNTR=mycobacterial interspersed repetitive units-
variable number of tandem repeats. WGS=whole genome sequencing. *These techniques type strains of M tuberculosis. 
 
Table: Measures of Mycobacterium tuberculosis transmission in populations  
  
    
Figure: Mycobacterium tuberculosis transmission cycle 
IGRA=interferon-gamma release assay. TST=tuberculin skin test. 
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